Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oesophageal cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    155 result(s) found for: Oesophageal cancer. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2006-001097-24 Sponsor Protocol Number: OE7-432-LOR-0033-I Start Date*: 2007-07-19
    Sponsor Name:Technische Universitaet Muenchen, Medizinische Fakultaet
    Full Title: Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.
    Medical condition: Locally advanced oesophageal squamous cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001834-34 Sponsor Protocol Number: 4919 Start Date*: 2006-03-14
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Phase 2 trial of neo-adjuvant Oxaliplatin and 5-fluorouracil in oesophageal cancer
    Medical condition: Operable oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013877-16 Sponsor Protocol Number: Number 1 Start Date*: 2009-10-30
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study
    Medical condition: oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    12 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005556-10 Sponsor Protocol Number: CA209-577 Start Date*: 2016-05-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
    Medical condition: Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030191 Oesophageal squamous cell carcinoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030190 Oesophageal squamous cell carcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030143 Oesophageal adenocarcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030144 Oesophageal adenocarcinoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned) FR (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001335-24 Sponsor Protocol Number: 141190 Start Date*: 2021-08-06
    Sponsor Name:Aarhus University
    Full Title: Thromboprophylaxis in Oesophageal Cancer Patients – A Randomized, Controlled Trial
    Medical condition: Thromboembolism in oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10030176 Oesophageal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003965-27 Sponsor Protocol Number: OCTO-072 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Oxford
    Full Title: A phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other sold cancers using time to event continual reassessment method
    Medical condition: Stage A1 and B: Oesophageal carcinoma Stage A2: Any advanced solid tumours (carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002617-35 Sponsor Protocol Number: BUL-5/ESD Start Date*: 2019-08-20
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for p...
    Medical condition: Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030186 Oesophageal squamous cell carcinoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10017947 - Gastrointestinal disorders 10004137 Barrett's oesophagus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) PT (Trial now transitioned) NL (Trial now transitioned) BE (Completed) SE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004744-11 Sponsor Protocol Number: PERFECT Start Date*: 2017-02-27
    Sponsor Name:Academic Medical Center
    Full Title: PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT)
    Medical condition: oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004024-12 Sponsor Protocol Number: STO-304-LOR-0092-I Start Date*: 2005-04-05
    Sponsor Name:Technical University of Munich
    Full Title: Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma
    Medical condition: advanced gastro-oesophageal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000640-10 Sponsor Protocol Number: 2012/VCC/0009 Start Date*: 2012-12-13
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carbopla...
    Medical condition: Histologically confirmed operable oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10056104 Squamous cell carcinoma of oesophagus LLT
    14.1 100000004864 10056092 Adenocarcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003836-77 Sponsor Protocol Number: OCTO-003 Start Date*: 2008-12-09
    Sponsor Name:University of Oxford
    Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.
    Medical condition: Barrett's Metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017137-22 Sponsor Protocol Number: 190178 Start Date*: 2013-04-16
    Sponsor Name:Klinische Abteilung für Thorax -u. Hyperbare Chirurgie, Medizinische Universität Graz
    Full Title: Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study.
    Medical condition: Patients admitted for treatment on a general thoracic surgery division with the following conditions: Lung cancer Esophageal cancer Cancer of the gastroesophageal junction (GEJ)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023377-19 Sponsor Protocol Number: D2610C00004 Start Date*: 2011-11-03
    Sponsor Name:AstraZeneca
    Full Title: A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Th...
    Medical condition: FGFR, Amplification, polysomy, gastro-oesophageal junction cancer, lower third oesophageal cancer, gastric cancer, randomised, efficacy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061967 Gastric cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030159 Oesophageal carcinoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017765 Gastric cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026104 Malignant neoplasm of lower third of esophagus LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000454-22 Sponsor Protocol Number: CCR4825 Start Date*: 2019-02-01
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer
    Medical condition: Advanced Oesophago-gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005298-19 Sponsor Protocol Number: LUD2015-005 Start Date*: 2016-03-08
    Sponsor Name:Ludwig Institute for Cancer Research Ltd.
    Full Title: Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer
    Medical condition: Oesophageal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026180 Malignant neoplasm of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-003306-13 Sponsor Protocol Number: CCR4557 Start Date*: 2017-05-16
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: CCR 4557: Peri-operative Immuno-Chemotherapy in Operable oesophageal aNd gastrIc Cancer (ICONIC Trial)
    Medical condition: Operable oesophageal and gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005391-13 Sponsor Protocol Number: OCTO_005 Start Date*: 2008-10-20
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2. Royal Wolverhampton Hospitals NHS Trust
    Full Title: Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa®) versus placebo in oesophageal cancer progressing after chemotherapy.
    Medical condition: Oesophageal cancer (adenocarcinoma and squamous cancers).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001141 Adenocarcinoma LLT
    9.1 10041824 Squamous cell carcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004624-38 Sponsor Protocol Number: BOT112-02 Start Date*: 2020-06-11
    Sponsor Name:Highlight Therapeutics, S.L
    Full Title: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophagea...
    Medical condition: Colorectal cancer or gastric/gastro-oesophageal junction cancer with liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002056-86 Sponsor Protocol Number: AIO-STO-0117 Start Date*: 2017-12-20
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer
    Medical condition: advanced esophageal squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015363 Esophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030152 Oesophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062478 Esophageal cancer metastatic LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 12 20:21:13 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA